Genomics and proteomics are two subfields of molecular biology that study the structure and function of living organisms at a molecular level. Genomics is the study of an organism’s full set of genes in order to understand the genetic processes that control their growth and behavior. Proteomics is the study of an organism’s proteins, which are the molecular machines that control the functioning of cells in the body. Both disciplines are important to gaining insight into the workings of the human body, from the genetic basis of disease to better understanding how food and drugs are metabolized. Genomics is the science of characterizing and studying an organism’s entire genetic context, which consists of its DNA, RNA, and proteins. By determining the condensed sequence of an organisms’ genome, scientists are able to create detailed information on the genetic basis of its phenotype and learn more about the molecular functioning of its gene products. By understanding gene-disease associations, scientists can identify mutated genes associated with various diseases and develop treatments based on this knowledge. Genomics also helps us understand an organism’s evolutionary history and the degree of gene flow from one generation to the next. Proteomics is the science of systematically analyzing all of the proteins in a single organism in order to gain a better understanding of the cellular processes and biological pathways that are active in the organism. Proteins are the large molecular machines that make up the majority of the functioning cell, and by studying their interactions with other molecules, scientists can gain insight into how different diseases develop and spread throughout an organism’s body. Proteomics also informs our understanding of how drugs can be used to target a specific protein, and can aid in drug development by helping to identify mechanisms of action for potential therapeutic candidates. In conclusion, Genomics and Proteomics are powerful tools for biologists to study and understand the functioning of living organisms at the molecular level.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Examining the effects of prenatal neurotoxin exposure on the development of the prefrontal cortex and its impact on executive functioning and attentional capacities in children
David Joseph Sperbeck, Private practice, United States
Title : Neurojourney: A free, digital, and multilingual anticipatory guidance tool for parents and clinicians caring for children with severe neurological impairment
Blyth Lord, Courageous Parents Network, United States
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : ACE-dependent Alzheimer’s Disease (AD)
Sergei M Danilov, University of Illinois, United States